BridgeBio Oncology Therapeutics (BBOT) Interest Income - Total (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Interest Income - Total for 3 years, with the latest figure at $3.9 million in Q1 2026.

• Quarterly Interest Income - Total rose 118.02% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.6 million (changed N/A YoY) and the FY2025 annual result came in at $11.3 million, up 77.87% from the prior year.
• Interest Income - Total declined to $3.9 million in Q1 2026 per BBOT's latest filing, from $4.4 million in the prior quarter.
• Over five years, Interest Income - Total peaked at $4.4 million in Q4 2025 and troughed at $1.8 million in Q1 2025.
• A 3-year average of $3.0 million and a median of $3.0 million in 2024 frame the typical range for Interest Income - Total.
• The sharpest annual moves came in 2025 and 2026: Interest Income - Total soared 39.26% in 2025, then jumped 118.02% in 2026.
• Over 3 years, Interest Income - Total stood at $2.1 million in 2024, then surged by 107.41% to $4.4 million in 2025, then fell by 10.85% to $3.9 million in 2026.
• According to Business Quant data, Interest Income - Total over the past three periods registered $3.9 million, $4.4 million, and $3.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.